Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATZUMI vs DIASTAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.
Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with PD-L1 expression ≥50%, with no EGFR or ALK genomic aberrations,First-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide,First-line treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic aberrations, in combination with bevacizumab, paclitaxel, and carboplatin,First-line treatment of metastatic squamous NSCLC in combination with paclitaxel and carboplatin,Treatment of locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, or in cisplatin-ineligible patients with PD-L1 expression,Treatment of metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (d MMR) after prior fluoropyrimidine, oxaliplatin, and irinotecan therapy,Off-label uses: Various solid tumors with PD-L1 expression or MSI-H/d MMR
Status epilepticus (FDA-approved for acute management),Breakthrough seizures in patients on stable antiepileptic regimen (FDA-approved),Preoperative anxiety (off-label),Alcohol withdrawal syndrome (off-label),Muscle spasm (off-label)
1.2 g intravenously every 12 hours over 10-12 hours.
Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
Terminal elimination half-life is 12-15 hours in patients with normal renal function (Cr Cl >90 m L/min), allowing once-daily dosing. Renal impairment prolongs half-life (up to 30 hours in Cr Cl 30-50 m L/min).
30–60 hours for diazepam; nordazepam (active metabolite) 50–120 hours. Prolonged in elderly, liver disease, and neonates
Metabolized via catabolic pathways into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Primarily hepatic via CYP2C19 and CYP3A4; active metabolite desmethyldiazepam (with long half-life); minor pathways include glucuronidation.
Approximately 70% of the dose is excreted renally as unchanged drug; 20% is eliminated via biliary/fecal routes as metabolites, with <5% as unchanged drug in feces.
Renal (primarily as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal minimal
95% bound to albumin and alpha-1-acid glycoprotein; binding is saturable at high concentrations.
98–99%; primarily albumin
2.5-3.5 L/kg, indicating extensive extravascular distribution (e.g., tissues, erythrocytes).
0.8–1.0 L/kg; increased in obesity (1.5–2.5 L/kg), redistribution to adipose tissue prolongs half-life
Oral: 70-80% (first-pass metabolism reduces bioavailability; food increases absorption by 15%).
Rectal: 90% (relative to IV, complete absorption). Oral: 100%
Cr Cl 30-60 m L/min: 1.2 g every 18 hours; Cr Cl 10-29 m L/min: 1.2 g every 24 hours; Cr Cl <10 m L/min: 1.2 g loading dose then 0.6 g every 24 hours.
No specific dose adjustment required for renal impairment; however, use with caution in severe impairment (Cr Cl <10 m L/min) due to prolonged half-life.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75% or avoid use.
Not approved for pediatric patients under 18 years.
Children 2-5 years: 0.5 mg/kg (max 20 mg) rectally. Children 6-11 years: 0.3 mg/kg (max 20 mg) rectally. Children 12+ years: same as adult dosing. May repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
No specific dose adjustment required; monitor renal function.
Initiate at lower end of dosing range (e.g., 0.1-0.15 mg/kg, max 10 mg) due to increased sensitivity and risk of falls; monitor for prolonged sedation and respiratory depression.
None.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin adverse reactions,Infusion-related reactions,Embryofetal toxicity,Increased risk of severe or fatal infection,Use caution in patients with autoimmune disease or organ transplant
Risk of respiratory depression, especially with concomitant CNS depressants; tolerance and physical dependence may develop; withdrawal symptoms including seizures after abrupt discontinuation; caution in elderly, debilitated patients, and those with hepatic impairment; may cause drowsiness or dizziness; not recommended for use in pregnancy (neonatal withdrawal).
Severe hypersensitivity to atzumi or any excipients,Active severe autoimmune disease requiring systemic immunosuppression (relative),Pregnancy (embryofetal toxicity)
Known hypersensitivity to diazepam or any benzodiazepine; myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; narrow-angle glaucoma (in patients receiving anticholinergic therapy).
Avoid alcohol consumption during therapy and for 48 hours after last dose due to risk of disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions known.
No specific food interactions. Avoid grapefruit juice as it may increase diazepam levels. Alcohol can potentiate CNS depression.
Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avoid unless benefit outweighs risk.
DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal symptoms postnatally; risk of floppy infant syndrome (hypotonia, lethargy, sucking difficulties) when administered near term.
No data on excretion in human milk; M/P ratio unknown. Caution advised; use only if clearly needed.
Diazepam is excreted into breast milk with an M/P ratio of approximately 0.2-0.5. The American Academy of Pediatrics recommends use with caution due to potential accumulation and sedation in the infant. Avoid chronic use; if necessary, monitor infant for sedation, poor feeding, and weight gain.
No established dosing adjustments; pharmacokinetic changes in pregnancy may alter exposure. Monitor therapeutic response and adjust dose empirically based on clinical efficacy and toxicity.
Due to increased volume of distribution and altered protein binding in pregnancy, total clearance of diazepam may be increased, potentially requiring higher doses to achieve therapeutic effect. However, routine dose adjustment is not recommended without clinical monitoring. Use lowest effective dose for shortest duration. Caution in third trimester due to increased risk of neonatal effects.
ATZUMI (aztreonam) is a monobactam antibiotic with activity against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. It is often used in patients with severe beta-lactam allergies (e.g., anaphylaxis to penicillins) due to minimal cross-reactivity. Monitor renal function (creatinine clearance) as dose adjustment is required in renal impairment. For cystic fibrosis patients, higher doses or continuous infusion may be considered. Administer over 20-60 minutes to reduce infusion-related phlebitis. Note: Inhaled aztreonam lysine (not ATZUMI) is used for chronic pulmonary infections in cystic fibrosis.
DIASTAT (diazepam rectal gel) is a formulation for acute management of seizure clusters. Administer rectally; monitor for respiratory depression, especially with concomitant CNS depressants. Do not exceed 5 doses per month or use for more than 5 episodes per month due to tolerance risk. Have flumazenil available for reversal.
Take this medication exactly as prescribed; do not skip doses or stop early unless instructed.,Report any signs of allergic reaction (rash, hives, itching, difficulty breathing, swelling of face/tongue) immediately.,Infusion site reactions (redness, swelling, pain) are common; notify healthcare provider if severe.,This drug may cause diarrhea, especially if prolonged; contact your doctor if watery or bloody stools occur.,Avoid alcohol while on this medication to reduce risk of disulfiram-like reaction (nausea, vomiting, headache).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Complete full course even if you feel better to prevent antibiotic resistance.
Use only as directed for episodes of increased seizure activity.,Administer rectally; do not reuse diapers/suppositories.,Monitor for drowsiness, dizziness, or breathing problems.,Avoid alcohol and other CNS depressants.,Store at room temperature; protect from light.,Seek emergency care if seizures last longer than usual or breathing is difficult.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATZUMI vs DIASTAT, answered by our medical review team.
ATZUMI is a Benzodiazepine Anticonvulsant that works by Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.. DIASTAT is a Benzodiazepine Anticonvulsant that works by Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATZUMI and DIASTAT depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATZUMI is: 1.2 g intravenously every 12 hours over 10-12 hours.. The standard adult dose of DIASTAT is: Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATZUMI and DIASTAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATZUMI is classified as Category C. Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avo. DIASTAT is classified as Category C. DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.